Diagnostics
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
The U.S. Food and Drug Administration has authorized the first non-prescription, over-the-counter, at-home antigen test that can be used to identify infection with SARS-CoV-2, the virus responsible for COVID-19, in people two years of age or older.
Detecting the presence of SARS-CoV-2 in asymptomatic individuals has been a challenge not even PCR – the gold standard of testing – can adequately address. Now two companies have developed novel solutions with the sensitivity and specificity needed to provide ample warning.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
All eyes on the FDA as they review a COVID-19 vaccine, FDA approval of an Emergency Use Authorization to LabCorp’s home test kit for COVID-19, the first testing device that does not require a prescription and more news.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
Nucleic-acid-based assays are the gold standard for detecting the presence of the SARS-CoV-2 virus, but they eventually will be replaced with simpler and more advanced techniques, such as CRISPR-Cas, LAMP, and other faster and less-expensive methods.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
California-based Grail aims to alter the devastating trajectory of cancer mortality with the addition of one simple blood test.
PRESS RELEASES
